Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 24 Oct 2017 Status changed from active, no longer recruiting to completed.
- 09 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual end date Sep 2010 added as reported by ClinicalTrials.gov.